

## Special Issue

# Bacterial and Viral Infection and Sepsis: From Pathogenesis to Therapeutic Strategies

### Message from the Guest Editor

The growing interest in sepsis is associated with the recognition that it is, today, one of the most common and life-threatening conditions. Since bacterial infection is the main cause of sepsis, viral sepsis is often ignored, but the global spread of COVID-19 has changed the urgency. Importantly, platelet hyperactivity, thrombotic complication, and coagulopathy are relevant issues that can lead to multiple organ failure (MOF). Timely diagnosis is essential to initiate effective treatment and to reduce the morbidity and mortality of sepsis. However, the diagnosis of sepsis remains a challenge, possibly related to the clinical complexity and dynamic characteristics of this disease. There is an enormous effort to investigate the pathophysiology of sepsis and the underlying mechanisms responsible for MOF in order to develop new biomarkers and early treatments in translational medical research. We are looking forward to improving outcomes in sepsis. As such, this Special Issue of *Biomedicines* will focus on bacterial and viral sepsis and bring new insights into the genetics, pathophysiology, diagnosis, biomarkers, and treatment.

### Guest Editor

Prof. Dr. Giuseppe Montrucchio  
Department of Medical Science, University of Turin, Turin, Italy

### Deadline for manuscript submissions

closed (30 June 2022)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/91815](https://mdpi.com/si/91815)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).